# A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women

> **NCT02956837** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 406 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **BIOLOGICAL:** RSV Vaccine (GSK3003891A) formulation 1
- **BIOLOGICAL:** RSV Vaccine (GSK3003891A) formulation 2
- **BIOLOGICAL:** RSV Vaccine (GSK3003891A) formulation 3
- **DRUG:** Placebo (Formulation buffer S9b)

## Key facts

- **NCT ID:** NCT02956837
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-10
- **Primary completion:** 2017-08-30
- **Final completion:** 2018-02-05
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2019-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02956837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02956837, "A Study to Rank Different Dosages of Antigen of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3003891A), Based on Their Immune Response and Safety, When Administered to Healthy Adult Women". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02956837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*